

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.*

Attachment 7  
August 25, 2026

【Therapeutic category】 429 Other antitumor agents  
【Non-proprietary name】 Apalutamide  
【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

| Current                                                                       | Revision                                                                                                                                                                                             |
|-------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 8. IMPORTANT PRECAUTIONS<br>N/A                                               | 8. IMPORTANT PRECAUTIONS<br><u>Agranulocytosis, neutropenia, or leukopenia may occur. Patients should be carefully monitored through periodic blood tests, etc. during treatment with this drug.</u> |
| 11. ADVERSE REACTIONS<br>11.1 Clinically Significant Adverse Reactions<br>N/A | 11. ADVERSE REACTIONS<br>11.1 Clinically Significant Adverse Reactions<br><u>Agranulocytosis, neutropenia, leukopenia</u>                                                                            |

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*